NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function

British Journal of Pharmacology

Volumn 173, Issue 3, 2016, Pages 613-626

  Ye, Shunan ^a,c   Zhang, Jianming ^a   Shen, Jacson ^a   Gao, Yan ^a   Li, Ying ^a   Choy, Edwin ^a   Cote, Gregory ^a   Harmon, David ^a   Mankin, Henry ^a   Gray, Nathanael S ^b   Hornicek, Francis J ^a   Duan, Zhenfeng ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 4 [[2 (ISOPROPYLSULFONYL)PHENYL]AMINO] 2 [[2 METHOXY 4 [4 (4 METHYL 1 PIPERAZINYL) 1 PIPERIDINYL]PHENYL]AMINO]PYRIMIDINE; ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATASE PGP1; BREAST CANCER RESISTANCE PROTEIN; DOCETAXEL; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROTEIN KINASE B; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRABECTEDIN; UNCLASSIFIED DRUG; VERAPAMIL; VINCRISTINE; ANTINEOPLASTIC AGENT; NVP-TAE684; P-GLYCOPROTEIN 2; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG UPTAKE; EC50; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MULTIDRUG RESISTANCE; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN HYDROLYSIS; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; OSTEOSARCOMA; P-GLYCOPROTEINS; PACLITAXEL; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 84956784879     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13395     Document Type: Article

References (52)

1. Agarwal R, Kaye SB, (2003). Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3: 502-516.
2. Ahmed-Belkacem A, Pozza A, Munoz-Martinez F, Bates SE, Castanys S, Gamarro F, et al.,. (2005). Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res 65: 4852-4860.
3. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al.,. (2015a). The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors. Br J Pharmacol 172: 5979-6023.
4. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al.,. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024-6109.
5. Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, et al.,. (2015c). The Concise Guide to PHARMACOLOGY 2015/16: Transporters. Br J Pharmacol 172: 6110-6202.
6. Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE, (2012). Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy 15: 50-61.
7. Choi CH, Kim JH, Kim SH, (2004). Reversal of P-glycoprotein-mediated MDR by 5,7,3′,4′,5′-pentamethoxyflavone and SAR. Biochem Biophys Res Commun 320: 672-679.
8. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, et al.,. (1996). Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56: 4171-4179.
9. Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J, et al.,. (2009a). Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. Mol Cancer Ther 8: 2122-2130.
10. Duan Z, Choy E, Hornicek FJ, (2009b). NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance. PLoS One 4: e7415.
11. Duan Z, Choy E, Jimeno JM, Cuevas Cdel M, Mankin HJ, Hornicek FJ, (2009c). Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines. Cancer Chemother Pharmacol 63: 1121-1129.
12. Duan Z, Feller AJ, Toh HC, Makastorsis T, Seiden MV, (1999). TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. Gene 229: 75-81.
13. Duan Z, Zhang J, Ye S, Shen J, Choy E, Cote G, et al.,. (2014). A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells. BMC Cancer 14: 681.
14. Ferry DR, Traunecker H, Kerr DJ, (1996). Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 32A: 1070-1081.
15. Fojo T, Bates S, (2003). Strategies for reversing drug resistance. Oncogene 22: 7512-7523.
16. Fojo T, Menefee M, (2007). Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 18 (Suppl 5): v3-v8.
17. Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L, et al.,. (2007). Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A 104: 270-275.
18. Garrigues A, Nugier J, Orlowski S, Ezan E, (2002). A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein. Anal Biochem 305: 106-114.
19. Gill J, Ahluwalia MK, Geller D, Gorlick R, (2013). New targets and approaches in osteosarcoma. Pharmacol Ther 137: 89-99.
20. Goda K, Bacso Z, Szabo G, (2009). Multidrug resistance through the spectacle of P-glycoprotein. Curr Cancer Drug Targets 9: 281-297.
21. Karthikeyan S, Hoti SL, (2015). Development of fourth generation ABC inhibitors from natural products: A novel approach to overcome cancer multidrug resistance. Anticancer Agents Med Chem 15: 605-615.
22. Kathawala RJ, Gupta P, Ashby CR Jr, Chen ZS, (2015). The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade. Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy 18: 1-17.
23. Kaye SB, (2008). Reversal of drug resistance in ovarian cancer: where do we go from here? Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 26: 2616-2618.
24. Kelly RJ, Robey RW, Chen CC, Draper D, Luchenko V, Barnett D, et al.,. (2012). A pharmacodynamic study of the P-glycoprotein antagonist CBT-1(R) in combination with paclitaxel in solid tumors. Oncologist 17: 512.
25. Kim SY, Helman LJ, (2009). Strategies to explore new approaches in the investigation and treatment of osteosarcoma. Cancer Treat Res 152: 517-528.
26. Kitazaki T, Oka M, Nakamura Y, Tsurutani J, Doi S, Yasunaga M, et al.,. (2005). Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 49: 337-343.
27. Kobayashi E, Iyer AK, Hornicek FJ, Amiji MM, Duan Z, (2013). Lipid-functionalized dextran nanosystems to overcome multidrug resistance in cancer: A pilot study. Clin Orthop Relat Res 471: 915-925.
28. Kopecka J, Salzano G, Campia I, Lusa S, Ghigo D, de Rosa G, et al.,. (2014). Insights in the chemical components of liposomes responsible for P-glycoprotein inhibition. Nanomedicine: Nanotechnology, Biology, and Medicine 10: 77-87.
29. Krishna R, Mayer LD, (2000). Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 11: 265-283.
30. Li-Blatter X, Beck A, Seelig A, (2012). P-glycoprotein-ATPase modulation: the molecular mechanisms. Biophys J 102: 1383-1393.
31. Liu Y, Marks K, Cowley GS, Carretero J, Liu Q, Nieland TJ, et al.,. (2013). Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discovery 3: 870-879.
32. Lourda M, Trougakos IP, Gonos ES, (2007). Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of clusterin/apolipoprotein J. International Journal of Cancer Journal International du Cancer 120: 611-622.
33. Luetke A, Meyers PA, Lewis I, Juergens H, (2014). Osteosarcoma treatment-where do we stand? A state of the art review. Cancer Treat Rev 40: 523-532.
34. MacKeigan JP, Murphy LO, Blenis J, (2005). Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 7: 591-600.
35. Munagala S, Sirasani G, Kokkonda P, Phadke M, Krynetskaia N, Lu P, et al.,. (2014). Synthesis and evaluation of Strychnos alkaloids as MDR reversal agents for cancer cell eradication. Bioorg Med Chem 22: 1148-1155.
36. Pang Z, Feng L, Hua R, Chen J, Gao H, Pan S, et al.,. (2010). Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats. Mol Pharm 7: 1995-2005.
37. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, Davenport AP, McGrath JC, Peters JA, Southan C, Spedding M, Yu W, Harmar AJ,; NC-IUPHAR. (2014) The IUPHAR/BPS Guide to PHARMACOLOGY: An expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res 42 (Database Issue): D1098-106.
38. Perez RP, Hamilton TC, Ozols RF, Young RC, (1993). Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer 71 (4 Suppl): 1571-1580.
39. Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, et al., (2008). Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol 75: 1302-1312.
40. Scarborough GA, (2002). Molecular mechanism of the P-type ATPases. J Bioenerg Biomembr 34: 235-250.
41. Scarborough GA, (2003). Rethinking the P-type ATPase problem. Trends Biochem Sci 28: 581-584.
42. Shukla S, Chen ZS, Ambudkar SV, (2012). Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy 15: 70-80.
43. Sodani K, Tiwari AK, Singh S, Patel A, Xiao ZJ, Chen JJ, et al.,. (2012). GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance. Biochem Pharmacol 83: 1613-1622.
44. Susa M, Choy E, Yang C, Schwab J, Mankin H, Hornicek F, et al.,. (2010a). Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay. J Biomol Screen 15: 287-296.
45. Susa M, Iyer AK, Ryu K, Choy E, Hornicek FJ, Mankin H, et al.,. (2010b). Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One 5: e10764.
46. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM, (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234.
47. Twentyman PR, Bleehen NM, (1991). Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected]. Eur J Cancer 27: 1639-1642.
48. Weisberg E, Liu Q, Zhang X, Nelson E, Sattler M, Liu F, et al.,. (2013). Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells. PLoS One 8: e56473.
49. Yang X, Shen J, Gao Y, Feng Y, Guan Y, Zhang Z, et al.,. (2015). Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis. International Journal of Cancer. Journal International du Cancer. Int J Cancer 137: 2029-2039.
50. Zhang J, Deng X, Choi HG, Alessi DR, Gray NS, (2012). Characterization of TAE684 as a potent LRRK2 kinase inhibitor. Bioorg Med Chem Lett 22: 1864-1869.
51. Zhu HJ, Wang JS, Markowitz JS, Donovan JL, Gibson BB, Gefroh HA, et al.,. (2006). Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. J Pharmacol Exp Ther 317: 850-857.
52. Zhu X, Sui M, Fan W, (2005). In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel. Anticancer Res 25 (3B): 1953-1962.